Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 12:14 PM ET

Biotechnology

Company Overview of Oxford BioTherapeutics Limited

Company Overview

Oxford BioTherapeutics Limited is engaged in the development of antibody-based cancer drugs for the treatment of cancer. It offers therapeutic antibodies and diagnostics. The company also provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies. It has strategic partnerships with Seattle Genetics Inc., Medarex Inc., Biosite Inc., Amgen Inc., and GlaxoSmithKline; and a strategic alliance with A. Menarini Industrie Farmaceutiche Riunite Srl. Oxford BioTherapeutics Limited was formerly known as Oxford Genome Sciences (UK) Limited and changed its name to Oxford BioTherapeutics Limited. in December 2008. The company was incorporated in 2003 and ...

94a Milton Park

Abingdon

Oxon,  OX14 4RY

United Kingdom

Founded in 2003

Phone:

44 1235 861 770

Fax:

44 1235 861 771

Key Executives for Oxford BioTherapeutics Limited

Founder, Chief Executive Officer and Director
Chief Operations Officer and Executive Director
Senior Vice President of Protein Sciences
Senior Vice President of Non-Clinical Development
Head of Clinical Development
Compensation as of Fiscal Year 2014.

Oxford BioTherapeutics Limited Key Developments

Oxford BioTherapeutics Limited Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 11:00 AM

Oxford BioTherapeutics Limited Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 11:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

Oxford BioTherapeutics Limited Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM

Oxford BioTherapeutics Limited Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Esteban Pombo-Villar, Chief Operations Officer and Executive Director.

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim

Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration. The target was discovered using Oxford BioTherapeutics' proprietary OGAP® system. This represents the first option exercised under the companies' oncology target discovery and validation collaboration established in 2013. Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target. Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.

Similar Private Companies By Industry

Company Name Region
Biocompatibles International plc Europe
Onyvax Ltd. Europe
pSiMedica Limited Europe
Evgen Limited Europe
Alaska Food Diagnostics Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oxford BioTherapeutics Limited, please visit www.oxfordbiotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.